A composition for reducing microbial activity in an environment susceptible to microbial activity, comprising: metallic nanoparticles; and an oxygenation agent.

Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier when topically applied to a subject, providing an easily applied barrier for protecting lesions and other wounds from external infective agents.

Systems and methods for treating drug resistant pneumonia and tuberculosis using hypochlorous acid (HOCl) are disclosed. Embodiments of the present disclosure relate to nebulizing HOCl as a method of treating drug resistant bacteria, in particular, bacterial pneumonia pathogens (i.e., Streptococcus pneumoniae) and Mycobacterium tuberculosis bacteria. The nebulized HOCl solution may be approximately 180 parts per million (PPM) of the aqueous solution and have a pH of less than 6.

Use of a compound having the formula (I) in the manufacture of a medicament for the prevention or treatment of a disease caused by oral bacteria in an animal wherein R1 is a straight or branched alkyl group containing 8 to 16 carbon atoms at the 2- or 3-position of the morpholino ring, and R2 is a straight or branched alkyl group containing 2 to 10 carbon atoms, substituted with a hydroxy group except in the alpha-position, or a pharmaceutically acceptable salt thereof. A cosmetic method of preventing or decreasing oral staining in an animal, comprising the step of exposing the oral cavity to a morpholino compound of general. ##STR00001##

Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.

1H-pyrazolo[4,3-g]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)

Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-l-antitrypsin modulators for treating alpha-l-antitrypsin deficiency (AATD)

Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Power sources that enable in-body devices, such as implantable and ingestible devices, are provided. Aspects of the in-body power sources of the invention include a solid support, a first high surface area electrode and a second electrode. Embodiments of the in-power sources are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the power sources of the invention.